ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 48.8 | 56.5 | 35.2 |
| Other income | 2.1 | 1.3 | 1.4 |
| Total income | 50.9 | 57.8 | 36.5 |
| Profit before exceptional items & tax | 10.3 | 10.6 | 5.0 |
| Profit before tax | 10.3 | 10.6 | 5.0 |
| Net profit | 6.7 | 8.5 | 4.0 |
| Operating margin | 20.2% | 18.3% | 13.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +67.50% |
|---|---|
| Net profit, quarter on quarter | -21.20% |
| Revenue, year on year | +38.60% |
BSE results filing, NSE: TITANBIO. Figures extracted from the filing.
Titan Biotech Ltd: key numbers
- Share price
- ₹376.95
- Market cap
- ₹1,947 Cr
- Revenue (annual)
- ₹206.2 Cr
- Net profit (annual)
- ₹29.89 Cr
- P/E (TTM)
- 50.4×Sector 35.5×
- Promoter holding
- 55.78%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Titan Biotech Ltd
All →Titan Biotech Q2 FY27 Results: Net Profit ₹12.5 Cr, Up 60.3% YoY
Titan Biotech Ltd reported revenue from operations of ₹76.5 Cr (+40.6% YoY) and net profit of ₹12.5 Cr (+60.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.5 Cr · +60.3% YoY
Titan Biotech Board Meeting Date
Titan Biotech's board meets 05 November 2026 to consider unaudited quarterly and half-year results. Trading window stays closed until 48 hours after outcome declaration.
Titan Biotech Bonus Issue
Titan Biotech allotted 1,03,29,625 bonus shares of Rs. 2 each in a 1:4 ratio. Paid-up capital rose to Rs. 10.33 Crore post-allotment.
Titan Biotech Other Announcement
Titan Biotech Limited has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Titan Biotech Bonus Issue
Titan Biotech Ltd fixed October 23, 2026, as the record date for its 1:4 bonus share issue. Allotment is scheduled for October 26, 2026.
Titan Biotech Capital Structure Change
Titan Biotech increased its authorised share capital from Rs. 10 Crore to Rs. 10.40 Crore, following shareholder approval at the 34th Annual General Meeting.